Daniel O'Neill - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Daniel O'Neill

Showing results (31-40 of 33) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 33 results.

The Lancet. Neurology|November 19, 2022

Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trialMichael J Soileau, Jason Aldred, Kumar Budur, et al.

Cell Reports. Medicine|August 26, 2025

AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertionsAisha M Swaih, Sara Talbot, Adriana Savoca, et al.

Journal of Medicinal Chemistry|September 7, 2021

Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated ResistanceM Raymond V Finlay, Peter Barton, Sue Bickerton, et al.

Pageof 4

Search research articles

Showing results (31-40 of 33) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 33 results.

The Lancet. Neurology|November 19, 2022

Cell Reports. Medicine|August 26, 2025

AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertionsAisha M Swaih, Sara Talbot, Adriana Savoca, et al.

Journal of Medicinal Chemistry|September 7, 2021

Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated ResistanceM Raymond V Finlay, Peter Barton, Sue Bickerton, et al.

Pageof 4